

Annexure V

Extract of Annual Return

FORM NO. MGT-9

as on the financial year ended 31st March, 2020

[Pursuant to Section 92(3) of the Companies Act, 2013 and
Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. Registration and other Details

i)	CIN	L24239MH1935PLC002380
ii)	Registration Date	17 th August, 1935
iii)	Name of the Company	Cipla Limited
iv)	Category	Public Company
	Sub-Category of the Company	Limited by shares
v)	Address of the Registered office and contact details	Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013 Tel: (022) 2482 6000 Fax: (022) 2482 6120 Email: cosecretary@cipla.com Website: www.cipla.com
vi)	Whether listed company	Yes
vii)	Name, Address and Contact details of Registrar & Transfer Agent	KFin Technologies Private Limited Selenium Tower B, Plot No.: 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500032, Telangana Tel: (040) 6716 2222 / 6716 1511 Fax: (040) 2300 1153 Email: einward.ris@kfintech.com

II. Principal business activities of the Company

Sr. No.	Name and Description of main products / services	NIC Code of the product / service	% to total turnover of the Company
i)	Pharmaceuticals	210	100

III. Particulars of Holding, Subsidiary and Associate Companies¹

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable section of the Companies Act, 2013
Subsidiaries (held directly)					
1	Goldencross Pharma Limited (formerly known as Goldencross Pharma Private Limited) Unit No.SB-901 & SB-902, Empire Tower Building, Gut No.31, Cloud City Campus, Thane Belapur Road, Airoli, Navi Mumbai, Thane - 400708, Maharashtra, India	U24239MH2000PLC123766	Subsidiary	100.00%	2(87)

¹GRI 102-45

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable section of the Companies Act, 2013
2	Meditab Specialities Limited (formerly known as Meditab Specialities Private Limited) Unit No.SB-901 & SB-902, Empire Tower Building, GutNo.31, Cloud City Campus, Thane Belapur Road, Airoli, Navi Mumbai, Thane - 400708, Maharashtra, India	U23240MH1996PLC104442	Subsidiary	100.00%	2(87)
3.	Cipla BioTec Limited L-147/ B, Verna Industrial Area, Verna, South Goa, Goa - 403722, India	U24239GA2008PLC007374	Subsidiary	100.00%	2(87)
4.	Cipla Health Limited^^ FOFB-11, B Wing, Fourth Floor, Art Guild House Phoenix Marketcity, L.B.S Marg, Kurla (West), Mumbai - 400070, Maharashtra, India	U24100MH2015PLC267880	Subsidiary	95.46%	2(87)
5.	Cipla Pharmaceuticals Limited Unit No. SB-901 & SB-902, Empire Tower, Gut No.31, Cloud City Campus, Airoli, Navi Mumbai, Thane - 400708, Maharashtra, India	U24239MH2019PLC333266	Subsidiary	100.00%	2(87)
6.	Jay Precision Pharmaceuticals Private Limited Government Indl Estate, Plot No. 40/41 ABCD, Charkop, Kandivali (West), Mumbai - 400 067, Maharashtra, India	U33111MH2012PTC234037	Subsidiary	60.00%	2(87)
7.	Cipla (Mauritius) Limited* C/o IQ EQ Corporate Services (Mauritius) Limited, 33 Edith Cavell Street, Port Louis, 11324, Mauritius	NA	Subsidiary	100.00%	2(87)
8.	Cipla Medpro South Africa (Pty) Limited 1474 South Coast Road, Mobeni, Durban, Kwa-Zulu Natal 4052, South Africa	NA	Subsidiary	100.00%	2(87)
9.	Cipla Holding B.V. Cipla Eurla, Antonie Van Leeuwenhoeklaan 9, Building A8, 2 nd Floor, 3721 MA Bilthoven, The Netherlands	NA	Subsidiary	100.00%	2(87)
10.	Cipla (EU) Limited Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, United Kingdom	NA	Subsidiary	100.00%	2(87)

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable section of the Companies Act, 2013
11.	Saba Investment Limited Office No. 601, Level 6, Emaar Square Building 3, Downtown Dubai, Dubai PO BOX 4254, UAE	NA	Subsidiary	51.00%	2(87)
Subsidiaries (held indirectly)					
12.	Medispray Laboratories Private Limited Plot No.344/345, Kundaim Industrial Estate, Kundaim, Goa - 403 115, India	U52311GA1992PTC002801	Subsidiary	100.00%	2(87)
13.	Sitec Labs Limited (formerly known as Sitec Labs Private Limited) Unit No.SB-901 & SB-902,Empire Tower Building, GutNo.31,Cloud City Campus, Thane Belapur Rd, Airoli Navi Mumbai Thane MH 400708, India	U74999MH2000PLC129210	Subsidiary	100.00%	2(87)
14.	Cipla (UK) Limited* Dixcart House, Addlestone Road, Bourne Business Park, Addlestone, Surrey, KT15 2LE, United Kingdom	NA	Subsidiary	100.00%	2(87)
15.	Cipla Australia Pty. Limited BSA Partnership Pty Ltd, Level 15, 461 Bourke Street, Melbourne, VIC, 3000, Australia	NA	Subsidiary	100.00%	2(87)
16.	Meditab Holdings Limited C/o IQ EQ Corporate Services (Mauritius) Ltd, 33 Edith Cavell Street, Port Louis, 11324, Mauritius	NA	Subsidiary	100.00%	2(87)
17.	Cipla USA Inc. 919 North Market Street, Suite 950, Wilmington, New castle Delaware 19801, USA	NA	Subsidiary	100.00%	2(87)
18.	Cipla Kenya Limited Purshottam Place, 8 th Floor, Cipla Limited, Museum Hill, Westlands Road, Westlands, Nairobi, 46986 - 00100, Kenya.	NA	Subsidiary	100.00%	2(87)
19.	Cipla Malaysia Sdn. Bhd. Suite 1005, 10 th Floor, Wisma Hamzah-Kwong Hing, No. 1, Leboh Ampang, 50100, Kuala Lumpur, Malaysia	NA	Subsidiary	100.00%	2(87)
20.	Cipla Europe NV De Keyserlei 58-60, Box 19, 2018 Antwerpen Belgium	NA	Subsidiary	100.00%	2(87)
21.	Inyanga Trading 386 Proprietary Limited* Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable section of the Companies Act, 2013
22.	Cipla Medpro Holdings Proprietary Limited* Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
23.	Cape to Cairo Exports Proprietary Limited** Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
24.	Cipla Dibcare Proprietary Limited* Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
25.	Cipla Life Sciences Proprietary Limited Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
26.	Cipla-Medpro Proprietary Limited Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
27.	Cipla-Medpro Distribution Centre Proprietary Ltd. Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
28.	Cipla Medpro Botswana Proprietary Limited P.O. Box 40185, Gaborone, Botswana	NA	Subsidiary	100.00%	2(87)
29.	Cipla OLTP (Pty) Limited (formerly known as Cipla Nutrition Pty Ltd) Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
30.	Medpro Pharmaceutical Proprietary Limited Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
31.	Breathe Free Lanka (Private) Limited No. 47, Alexandra Place, Colombo 07, Sri Lanka	NA	Subsidiary	100.00%	2(87)

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable section of the Companies Act, 2013
32.	Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda. City of Vargem Grande Paulista, State of Sao Paulo, at Estrada da Lagoinha, No. 489, block 2, Bairro da Lagoa, CEP 06730-000, Brazil	NA	Subsidiary	100.00%	2(87)
33.	Cipla Philippines Inc. Level 40, PBCom Tower, 6795 Ayala Avenue Corner V. A., Rufino Street, Makati City, Metro Manila, 1226, Philippines	NA	Subsidiary	100.00%	2(87)
34.	InvaGen Pharmaceuticals Inc. One Commerce Plaza 99 Washington Ave, Ste 805-A Albany, New York, 12210-2822, USA	NA	Subsidiary	100.00%	2(87)
35.	Exelan Pharmaceuticals Inc. 919 North Market Street, Suite 950, Wilmington, New castle Delaware 19801, USA	NA	Subsidiary	100.00%	2(87)
36.	Cipla Biotec South Africa (Pty) Limited Building 2, Maxwell Office Park, Magwa Crescent West, Waterfall City Midrand, Gauteng, South Africa	NA	Subsidiary	100.00%	2(87)
37.	Anmaraté (Pty) Limited Parc du Cap, Building 9, Mispel Street Bellville, Western Cape, 7530, South Africa	NA	Subsidiary	100.00%	2(87)
38.	Cipla Technologies LLC, 919 North Market Street, Suite 950, Wilmington, New castle Delaware 19801, USA	NA	Subsidiary	100.00%	2(87)
39.	Madison Pharmaceuticals Inc. 919 North Market Street, Suite 950, Wilmington, New castle Delaware 19801, USA	NA	Subsidiary	100.00%	2(87)
40.	Cipla Gulf FZ- LLC Unit No. 111, 1st floor DSP Laboratory Complex Dubai, United Arab Emirates	NA	Subsidiary	100.00%	2(87)
41.	Mirren (Pty) Limited 18 Golden Drive, Morehill Benoni, 1501, South Africa	NA	Subsidiary	100.00%	2(87)
42.	Cipla Maroc SA Casablanca-Bureau n°7-1, 7ème étage, 33 Avenue Hassan Sghir, Morocco	NA	Subsidiary	60.00%	2(87)

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable section of the Companies Act, 2013
43.	Cipla Pharma Lanka (Private) Limited ^c No 345- 4/1, Galle Roads, Colombo 03, Sri Lanka	NA	Subsidiary	100.00%	2(87)
44.	Cipla Quality Chemical Industries Limited Plot 1-7, First Ring Road, Luzira Industrial Park, P.O. Box 34871, Kampala, Uganda	NA	Subsidiary	51.18%	2(87)
45.	Cipla Middle East Pharmaceuticals FZ-LLC SD 2-50, Floor 03, DSP Laboratory complex, Dubai, United Arab Emirates	NA	Subsidiary	51.00%	2(87)
46.	Quality Chemicals Limited Quality Chemicals House, Plot 64/65 Katwe Road, P.O. Box 3381, Kampala, Uganda	NA	Subsidiary	51.00%	2(87)
47.	Medica Pharmaceutical Industries Company Limited Al-Jabal Group building, Noakshot Street, Behind Canada Dry Factory, Sanaa, Yemen	NA	Subsidiary	50.49%	2(87)
48.	Cipla (China) Pharmaceutical Co., Limited Room 203, 2 nd F, Building No.1, 1479 Zhangheng Rd., Shanghai, China	NA	Subsidiary	100.00%	2(87)
49.	Cipla Algérie 18, Rue de Zone Industrielle, Route De La Gare, Haouche Mahieddine, Reghala, Algeria	NA	Subsidiary	40.00%	2(87)
50.	Cipla (Jiangsu) Pharmaceutical Co., Limited No.168 Binjiang Road, Binjiang Fine Chemical Park, Qidong, Jiangsu Province of China, China	NA	Subsidiary	80.00%	2(87)
51.	Cipla Colombia SAS Cra 13 # 85 -39 ofc 505, Bogota, Colombia, 110221.	NA	Subsidiary	100.00%	2(87)
Associates (held indirectly)					
52.	Stempeutics Research Private Limited 3 rd Floor, #143, 212-215, EPIP Industrial Area Hoodi Village, K.R.Puram, Hobli Bengaluru - 560066, Karnataka, India	U73100KA2006PTC038256	Associate	40.78%	2(6)
53.	Avenue Therapeutics, Inc. 1140 Avenue of the Americas, Floor 9 New York, 10036, USA	NA	Associate	33.3%	2(6)

Sr. No.	Name and address of the Company	CIN/GLN	Holding/ Subsidiary /Associate	% of shares held	Applicable section of the Companies Act, 2013
54.	AMPSolar Power Systems Private Limited 309, 3 rd Floor, Rectangle One, Behind Sheraton Hotel, Saket, New Delhi - 110 017, India	U74996DL2019PTC345639	Associate	26.00%	2(6)
55.	Brandmed (Pty) Limited 22 1 st Avenue Houghton Estate 2198, South Africa	NA	Associate	30.00%	2(6)

* in process of liquidation

† Under amalgamation with Breathe Free Lanka (Private) Limited

** Under de-registration

^^ 95.46% is held by Cipla Limited and 4.54% is held through Cipla Health Employees Stock Option Trust

IV. Share Holding Pattern

(Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year (As on 1 st April, 2019)				No. of Shares held at the end of the year (As on 31 st March, 2020)				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual / HUF	114708572	-	114708572	14.24	114708572	-	114708572	14.23	-0.01
b) Central Govt.	-	-	-	-	-	-	-	-	-
c) State Govt(s)	-	-	-	-	-	-	-	-	-
d) Bodies Corp.	5869837	-	5869837	0.73	5869837	-	5869837	0.73	-
e) Banks / FI	-	-	-	-	-	-	-	-	-
f) Any other	-	-	-	-	-	-	-	-	-
Sub-total (A) (1)	120578409	-	120578409	14.97	120578409	-	120578409	14.96	-0.01
(2) Foreign									
(a) NRIs - Individuals	174907187	-	174907187	21.71	174907187	-	174907187	21.69	-0.01
(b) Other - Individuals	-	-	-	-	-	-	-	-	-
(c) Bodies Corp.	-	-	-	-	-	-	-	-	-
(d) Banks / FI	-	-	-	-	-	-	-	-	-
(e) Any other	-	-	-	-	-	-	-	-	-
Sub-total (A) (2)	174907187	-	174907187	21.71	174907187	-	174907187	21.69	-0.01
Total shareholding of Promoter (A) = (A) (1) + (A)(2)									
	295485596	-	295485596	36.67	295485596	-	295485596	36.65	-0.02
B. Public Shareholding									
1) Institutions									
a) Mutual Funds / UTI	82716685	-	82716685	10.27	136411887	-	136411887	16.92	6.65
b) Banks / FI	2826999	4100	2831099	0.35	2171342	4100	2175442	0.27	-0.08
c) Central Govt.	-	-	-	-	-	-	-	-	-
d) State Govt(s)	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	27344189	-	27344189	3.39	42435406	-	42435406	5.26	1.87

Category of Shareholders	No. of Shares held at the beginning of the year (As on 1 st April, 2019)				No. of Shares held at the end of the year (As on 31 st March, 2020)				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
g) Foreign Institutional Investors	5357355	-	5357355	0.66	100676	-	100676	0.01	-0.65
h) Foreign Venture Capital Funds	-	-	-	-	-	-	-	-	-
i) Others (specify)	-	-	-	-	-	-	-	-	-
•Foreign Portfolio Investors	209026785	-	209026785	25.94	144742733	-	144742733	17.95	-7.99
•Alternate Investment Funds	1290798	-	1290798	0.16	1324616	-	1324616	0.16	-
Sub-total (B)(1)	328562811	4100	328566911	40.78	327186660	4100	327190760	40.58	-0.20
2) Non-Institutions									
a) Bodies Corp.									
i) Indian	32163137	242812	32405949	4.02	33405642	242812	33648454	4.17	0.15
ii) Overseas	11729	-	11729	0.00	1306	-	1306	0.00	0.00
b) Individuals									
i) Individual shareholders holding nominal share capital upto ₹1 lakh	47971131	2155354	50126485	6.22	49229897	1743564	50973461	6.32	0.10
ii) Individual shareholders holding nominal share capital in excess of ₹1 lakh	68767359	10954037	79721396	9.89	69937849	7395425	77333274	9.59	-0.30
c) Others (specify)									
i) Qualified Foreign Investor	-	-	-	-	-	-	-	-	-
ii) Trusts	5905369	-	5905369	0.73	9391048	-	9391048	1.16	0.43
iii) Non Resident Indians / Foreign Nationals / Foreign Bodies	5222409	388200	5610609	0.70	5744567	388200	6132767	0.76	0.06
iv) Clearing Members	3413113	-	3413113	0.42	2225483	-	2225483	0.28	-0.15
v) Overseas Corporate Bodies	375	-	375	0.00	375	-	375	0.00	-
vi) NBFCs Registered with RBI	75022	-	75022	0.01	23690	-	23690	0.00	-0.01
vii) Investor Education and Protection Fund Authority Ministry of Corporate Affairs	3783374	-	3783374	0.47	3235083	-	3235083	0.40	-0.07
Sub-total (B)(2)	167313018	13740403	181053421	22.46	173194940	9770001	182964941	22.69	0.23
Total Public Shareholding (B)=(B)(1) + (B)(2)									
	495875829	13744503	509620332	63.25	500381600	9774101	510155701	63.28	0.03
C. Shares held by Custodian for GDRs & ADRs									
	595338	-	595338	0.07	594032	-	594032	0.07	-
Grand Total (A+B+C)	791956763	13744503	805701266	100.00	796461228	9774101	806235329	100.00	-

ii) Shareholding of Promoters and Promoter group

Sr. No.	Shareholder's Name	Shareholding at the beginning of the year (As on 1 st April, 2019)			Shareholding at the end of the year (As on 31 st March, 2020)			% change in shareholding during the year [^]
		No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	
1)	Dr Y K Hamied	163967687	20.35	-	163967687	20.34	-	0.01
2)	M K Hamied	34567572	4.29	-	34567572	4.29	-	-
3)	Alps Remedies Private Limited	492985	0.06	-	492985	0.06	-	-
4)	Sophie Ahmed	45982000	5.71	-	45982000	5.70	-	0.01
5)	Shirin Hamied	6363000	0.79	-	6363000	0.79	-	-
6)	Kamil Hamied	10939500	1.36	-	10939500	1.36	-	-
7)	Samina Hamied	17909500	2.22	-	17909500	2.22	-	-
8)	Rumana Hamied	9886500	1.23	-	9886500	1.23	-	-
9)	MN Rajkumar Garments LLP	5376852	0.67	-	5376852	0.67	-	-
10)	Shree Riddhi Chemicals LLP	0	0	-	0	0	-	-
12)	Hamsons Laboratories LLP	0	0	-	0	0	-	-
9)	Farida Hamied	0	0	-	0	0	-	-
13)	Neo Research Labs Private Limited	0	0	-	0	0	-	-
	Total	295485596	36.67	-	295485596	36.65	-	0.02

[^]The change in total percentage of shareholding is due to increase in the overall paid-up share capital of the Company.

iii) Change in Promoter and Promoter Group's Shareholding

There was no change in the Promoter and Promoter group shareholding during the FY 2019-20.

iv) Shareholding Pattern of top ten Shareholders

(other than Directors, Promoters and Holders of GDRs and ADRs)

Sr. No.	Name of the Shareholder	Shareholding		Cumulative Shareholding during the Year	
		No. of Shares	% of total shares of the Company	No. of Shares	% of total shares of the Company
1	ICICI Prudential Mutual Fund				
	At the beginning of the year	27505977	3.42	27505977	3.42
	Bought during the year	29284512	3.63	56790489	7.04
	Sold during the year	6114592	0.76	50675897	6.29
	At the end of the year	50675897	6.29	50675897	6.29
2	Life Insurance Corporation of India				
	At the beginning of the year	25017146	3.10	25017146	3.10
	Bought during the year	14562317	1.81	39579463	4.91
	Sold during the year	21100	0.003	39558363	4.91
	At the end of the year	39558363	4.91	39558363	4.91
3	HDFC Mutual Fund				
	At the beginning of the year	20249660	2.52	20249660	2.52
	Bought during the year	5676303	0.70	25925963	3.22
	Sold during the year	1381205	0.17	24544758	3.04
	At the end of the year	24544758	3.04	24544758	3.04

Sr. No.	Name of the Shareholder	Shareholding		Cumulative Shareholding during the Year	
		No. of Shares	% of total shares of the Company	No. of Shares	% of total shares of the Company
4	Aditya Birla Mutual Fund				
	At the beginning of the year	298299	0.04	298299	0.04
	Bought during the year	20740895	2.57	21039194	2.61
	Sold during the year	1361634	0.17	19677560	2.44
	At the end of the year	19677560	2.44	19677560	2.44
5	SBI Mutual Fund				
	At the beginning of the year	8793771	1.09	8793771	1.09
	Bought during the year	10942785	1.36	19736556	2.45
	Sold during the year	2896312	0.36	16840244	2.09
	At the end of the year	16840244	2.09	16840244	2.09
6	Government Pension Fund Global				
	At the beginning of the year	9591180	1.20	9591180	1.20
	Bought during the year	4089501	0.50	13680681	1.70
	Sold during the year	1205711	0.15	12474970	1.55
	At the end of the year	12474970	1.55	12474970	1.55
7	NPS Trust				
	At the beginning of the year	5333447	0.07	5333447	0.07
	Bought during the year	3499921	0.43	8833368	1.09
	Sold during the year	19926	0.00	8813442	1.09
	At the end of the year	8813442	1.09	8813442	1.09
8	UTI Mutual Fund				
	At the beginning of the year	7376111	0.92	7376111	0.92
	Bought during the year	4081522	0.50	11457633	1.42
	Sold during the year	2751396	0.34	8706237	1.08
	At the end of the year	8706237	1.08	8706237	1.08
9	HDFC Life Insurance Company Limited				
	At the beginning of the year	4533688	0.56	4533688	0.56
	Bought during the year	3555829	0.44	8089517	1.00
	Sold during the year	469562	0.06	7619955	0.95
	At the end of the year	7619955	0.95	7619955	0.95
10	Reliance Mutual Fund				
	At the beginning of the year	10225129	1.27	10225129	1.27
	Bought during the year	10635032	1.32	20860161	2.59
	Sold during the year	13864771	1.72	6995390	0.87
	At the end of the year	6995390	0.87	6995390	0.87

Shareholding is consolidated based on PAN irrespective of the schemes / sub-accounts.

Note: The above information is based on the weekly beneficiary position received from the depositories.

v) Shareholding of Directors and Key Managerial Personnel

Sr. No.	Name	Shareholding		Date	Increase / (Decrease) in shareholding	Reason	Cumulative Shareholding during the year (1 st April, 2019 to 31 st March, 2020)	
		No. of shares at the beginning (1 st April, 2019) / end of the year (31 st March, 2020)	% of total shares of the Company				No. of shares	% of total shares of the Company [^]
1)	Dr Y K Hamied	163967687	20.35	31/03/2019	-	-	163967687	20.35
		163967687	20.34 [^]	31/03/2020	-	-	163967687	20.34 [^]
2)	Mr M K Hamied	34567572	4.29	31/03/2019	-	-	34567572	4.29
		34567572	4.29	31/03/2020	-	-	34567572	4.29
3)	Ms Samina Hamied	17909500	2.22	31/03/2019	-	-	17909500	2.22
		17909500	2.22	31/03/2020	-	-	17909500	2.22
4)	Mr S Radhakrishnan [§]	142321	0.02	31/03/2019	-	-	142321	0.02
		-	-	16/09/2019	50000	Allotment pursuant to ESOS 2013-A	192321	0.02
		-	-	13/11/2019	50000	Allotment pursuant to ESOS 2013-A	242321	0.03
		242321	0.03	31/03/2020	-	-	242321	0.03
5)	Mr Umang Vohra	192256	0.02	31/03/2019	-	-	192256	0.02
		-	-	13/11/2019	55799	Allotment pursuant to ESOS 2013-A	248055	0.03
		248055	0.03	31/03/2020	-	-	248055	0.03
6)	Mr Kedar Upadhye	20280	0.00	31/03/2019	-	-	20280	0.00
		-	-	16/09/2019	20284	Allotment pursuant to ESOS 2013-A	40564	0.00
		40564	0.00	31/03/2020	-	-	40564	0.00

[§]38,125 shares are held jointly with his wife

[^]The change in total percentage of shareholding is due to increase in the overall paid-up share capital of the Company.

V) Indebtedness

Indebtedness of the Company including interest outstanding/accrued but not due for payment:

	₹ in Crore			
	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	-	-	-	-
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	-	-	-
Total (i+ii+iii)	-	-	-	-
Change in Indebtedness during the financial year				
•Addition	-	13.88	-	13.88
•Reduction	-	(7.82)	-	(7.82)
Net Change	-	6.06	-	6.06
Indebtedness at the end of the financial year				
i) Principal Amount	-	6.06	-	6.06
ii) Interest due but not paid	-	-	-	-
iii) Interest accrued but not due	-	0.01	-	0.01
Total (i+ii+iii)	-	6.07	-	6.07

VI. Remuneration of Directors and Key Managerial Personnel

i) Remuneration to Managing Director, Whole-time Directors and/or Manager

Sr. No.	Particulars of Remuneration	Name of MD/WTD/ Manager		Total Amount
		Ms Samina Hamied (Executive Vice-Chairperson)	Mr Umang Vohra (Managing Director and Global Chief Executive Officer)	
Gross salary				
1)	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	4.20	6.73	10.93
	(b) Value of perquisites u/s 17(2) of the Income-tax Act, 1961	0.02	0.00 ⁽¹⁾	0.02
	(c) Profits in lieu of salary u/s 17(3) of the Income-tax Act, 1961	-	-	-
2)	Stock Option	-	2.60 ⁽²⁾	2.60
3)	Sweat Equity	-	-	-
4)	Commission as % of profit	2.30	-	2.30
5)	-Other employer contribution to provident fund and other funds	0.23	0.23	0.46
	-Variable Bonus	-	4.00	4.00
	Total (A)	6.74	13.57	20.31
	Ceiling as per the Companies Act, 2013 ("the Act") (being 10% of the net profit of the Company calculated as per section 198 of the Act)			303.38

⁽¹⁾Since the value of perquisite is only ₹28,800/-, the amount has been shown as ₹0.00 crore.

⁽²⁾Value of perquisites u/s 17(2) of the Income-tax Act, 1961 does not include perquisite value of stock options exercised during FY 2019-20. The same has been shown separately in point no. (2).

ii) Remuneration to other directors

Sr. No.	Name of the Director	Fee for attending board / committee meeting	Commission	Others	₹ in Crore
					Total Amount
1)	Independent Directors				
	Mr Ashok Sinha	0.08	0.40	-	0.48
	Dr Peter Mugenyi ⁽¹⁾	0.05	0.41	-	0.46
	Mr Adil Zainulbhai	0.11	0.36	-	0.47
	Ms Punita Lal	0.05	0.35	-	0.40
	Ms Naina Lal Kidwai	0.10	0.35	-	0.45
	Mr Peter Lankau ^{(1) (2)}	-	0.10	-	0.10
	Total (1)	0.39	1.97	-	2.36
2)	Other Non-Executive Directors				
	Dr Y K Hamied	0.03	2.00	-	2.03
	Mr M K Hamied	0.08	2.00	-	2.08
	Mr S Radhakrishnan	0.10	2.00	4.63 ⁽³⁾	6.73
	Total (2)	0.21	6.00	4.63	10.84
	Total (B) = (1+2)	0.60	7.97	4.63	13.20
	Ceiling as per the Act (being 1% of the net profits of the Company calculated as per section 198 of the Act)				30.34
	Total Managerial Remuneration (A+B)				33.51
	Overall Ceiling as per the Act (being 11% of Net Profits of the Company calculated as per section 198 of the Act)				333.72

⁽¹⁾ USD equivalent to INR paid to the Directors.

⁽²⁾ Resigned from the position of Director w.e.f 1st July, 2019

⁽³⁾ Perquisite value of stock options granted in earlier years during his tenure as Whole Time Director but exercised in FY 2019-20

iii) Remuneration to Key Managerial Personnel other than MD/Manager/WTD

Sr. No.	Particulars of Remuneration	Key Managerial Personnel		Total Amount
		Mr Kedar Upadhye (Global Chief Financial Officer)	Mr Rajendra Chopra (Company Secretary)	
	Gross salary (A)			
1)	(a) Salary as per provisions contained in Section 17(1) of the Income-tax Act, 1961	1.70	1.09	2.79
	(b) Value of perquisites u/s 17(2) of the Income-tax Act, 1961	0.00 ⁽¹⁾	-	0.00
	(c) Profits in lieu of salary u/s 17(3) of the Income-tax Act, 1961	-	-	-
2)	Stock Option	0.94	-	0.94
3)	Sweat Equity	-	-	-
4)	Commission	-	-	-
5)	Others (B)	-	-	-
	- Employer contribution to provident fund and other funds	0.05	0.05	0.11
	- Variable Bonus	0.90	0.39	1.29
	Total (A+B)	3.60	1.53	5.13

⁽¹⁾ Since the value of perquisite is only ₹39,600/-, the amount has been shown as ₹0.00 crore.

VII. Penalties / Punishment / Compounding of Offences (under the Companies Act, 2013): None

On behalf of the Board,

Date: 15th May, 2020
Place: London

Y K Hamied
Chairman